# Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma

> **NCT06463548** · NA · NOT_YET_RECRUITING · sponsor: **Yunpeng Liu** · enrollment: 30 (estimated)

## Conditions studied

- Biliary Tract Carcinoma

## Interventions

- **DRUG:** irinotecan hydrochloride liposome injection
- **DRUG:** Capecitabine
- **DRUG:** Lenvatinib

## Key facts

- **NCT ID:** NCT06463548
- **Lead sponsor:** Yunpeng Liu
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06463548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06463548, "Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06463548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*